Phosphotransacetylase inhibitors are specialized compounds designed to target phosphotransacetylase (EC 2.3.1.8), an enzyme crucial in the metabolic pathways of microorganisms and some eukaryotic cells. Phosphotransacetylase catalyzes the reversible conversion between acetyl-CoA and acetyl phosphate, playing a significant role in acetate metabolism and energy production. This enzyme facilitates the transfer of an acetyl group from acetyl-CoA to inorganic phosphate, generating acetyl phosphate and Coenzyme A (CoA). Acetyl phosphate serves as a key intermediate in various biochemical processes, including substrate-level phosphorylation and signaling pathways. By modulating the activity of phosphotransacetylase, inhibitors can influence the flow of metabolites through these critical pathways, affecting cellular energy dynamics and metabolic regulation.
The chemical class of phosphotransacetylase inhibitors includes a range of molecules engineered to interact specifically with the active site or regulatory regions of the enzyme. These compounds may consist of substrate analogs that mimic acetyl-CoA or acetyl phosphate, competitively binding to the active site and preventing the natural substrates from accessing it. Other inhibitors might target allosteric sites, inducing conformational changes that reduce enzymatic activity. Development of these inhibitors involves advanced techniques such as structure-based drug design, where detailed knowledge of the enzyme's three-dimensional structure guides the creation of molecules with high specificity and affinity. High-throughput screening methods are also employed to identify potential inhibitors from extensive chemical libraries. Researchers utilize phosphotransacetylase inhibitors as valuable tools to dissect the enzyme's mechanism of action, study metabolic flux in biochemical pathways, and explore the regulatory networks governing energy production and acetate metabolism in cells.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Triclosan | 3380-34-5 | sc-220326 sc-220326A | 10 g 100 g | $138.00 $400.00 | ||
Triclosan may hamper bacterial DNA replication by inhibiting DNA gyrase, which could lead to a proportional decrease in the transcription of various genes, including those coding for PTA. | ||||||
Rifampicin | 13292-46-1 | sc-200910 sc-200910A sc-200910B sc-200910C | 1 g 5 g 100 g 250 g | $95.00 $322.00 $663.00 $1438.00 | 6 | |
Rifampicin could specifically bind to bacterial RNA polymerase, obstructing the initiation phase of transcription and consequentially reducing the synthesis of PTA mRNA. | ||||||
Chloramphenicol | 56-75-7 | sc-3594 | 25 g | $53.00 | 10 | |
By binding to the bacterial 50S ribosomal subunit, Chloramphenicol might block the elongation of protein synthesis, leading to a reduction in the production of PTA. | ||||||
Quinacrine, Dihydrochloride | 69-05-6 | sc-204222 sc-204222B sc-204222A sc-204222C sc-204222D | 100 mg 1 g 5 g 200 g 300 g | $45.00 $56.00 $85.00 $3193.00 $4726.00 | 4 | |
Quinacrine can intercalate into bacterial DNA, potentially disrupting transcriptional processes and therefore leading to a decrease in PTA gene expression. | ||||||
Mitomycin C | 50-07-7 | sc-3514A sc-3514 sc-3514B | 2 mg 5 mg 10 mg | $65.00 $99.00 $140.00 | 85 | |
Mitomycin C forms crosslinks within DNA strands, which may inhibit transcription and replication, potentially resulting in a diminished expression of the PTA enzyme. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
Actinomycin D binds tightly to DNA, obstructing the advancement of RNA polymerase during transcription, which could lead to a lowered production of PTA transcripts. | ||||||
Puromycin | 53-79-2 | sc-205821 sc-205821A | 10 mg 25 mg | $163.00 $316.00 | 436 | |
Puromycin might cause premature termination of mRNA translation, which could lead to incomplete protein synthesis and a consequent reduction in PTA enzyme levels. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
In eukaryotic organisms, Cycloheximide impedes the translocation step of protein synthesis, which could indirectly lead to a downregulation of PTA enzyme production. | ||||||
Gentamicin sulfate | 1405-41-0 | sc-203334 sc-203334A sc-203334F sc-203334B sc-203334C sc-203334D sc-203334E | 1 g 5 g 50 g 100 g 1 kg 2.5 kg 7.5 kg | $55.00 $175.00 $499.00 $720.00 $1800.00 $2600.00 $6125.00 | 3 | |
Gentamicin, an aminoglycoside, could cause incorrect mRNA reading during protein synthesis, potentially leading to the synthesis of dysfunctional PTA or its lowered expression. | ||||||
Tetracycline | 60-54-8 | sc-205858 sc-205858A sc-205858B sc-205858C sc-205858D | 10 g 25 g 100 g 500 g 1 kg | $62.00 $92.00 $265.00 $409.00 $622.00 | 6 | |
Tetracycline can bind to the 30S ribosomal subunit, inhibiting the binding of aminoacyl-tRNA and thereby leading to a decreased rate of protein synthesis, including that of PTA. |